Bank of Montreal
RLMD icon

Bank of Montreal’s Relmada Therapeutics RLMD Stock Holding History

Bank of Montreal’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-21,600
Closed -$826K – 5084
2020
Q3 		$826K Sell
21,600
-12,000
-36% -$464K ﹤0.01% 2067
2020
Q2 		$1.42M Buy
+33,600
New +$1.42M ﹤0.01% 1781

Other funds holding RLMD

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Bank of Montreal's RLMD Position: Q3 2024 in Review

Bank of Montreal sold out of Relmada Therapeutics (RLMD) in Q3 2024, closing a stake of 19,900 shares — an estimated $62.7K sold.

Bank of Montreal first reported a position in RLMD in Q2 2020 and held it in 5 quarters. The position peaked at $80K in Q4 2020. 69 funds tracked by Wall St. Rank hold RLMD as of Q3 2024.

  • Bank of Montreal reported no remaining Relmada Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Bank of Montreal sold 19,900 Relmada Therapeutics shares in Q3 2024, an estimated $62.7K.
  • Bank of Montreal first reported a position in Relmada Therapeutics in Q2 2020 and held it in 5 quarters.
  • Bank of Montreal's Relmada Therapeutics position peaked at $80K in Q4 2020.
  • 69 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2024.

Based on Bank of Montreal's 13F filing for Q3 2024, filed 13 Nov 2024.